|Clinical and Regulatory|
|Event Type:||Phase 3 Results|
This event is set for a broad date range and therefore the exact timing is unknown. This adds a degree of risk.
|Disease and Treatment|
|Indication:||Exocrine Pancreatic Insufficiency in Patients with Cystic Fibrosis|
|Treatment Name:||Sollpura (liprotamase)|
Likelihood of event success varies depending on disease, treatment and lead indication classification.
|Co. Name:||Anthera Pharmaceuticals|
The OTC BB and OTC Markets have less stringent reporting and financial requirements than the NASDAQ and NYSE. This may increase the level of risk for investors. Smaller size may have an influence on likelihood of success.
Partnerships help smaller biotech companies finance the long approval process. Partnership also provides validation the clinical program may be a worthy investment.
Detailed Event Description from Company Announcement
Phase 3 SOLUTION Clinical Study Enrollment Target of 126 Patients Met
We met the enrollment target in our Phase 3 SOLUTION clinical study evaluating the efficacy and safety of the capsule formulation of Sollpura™ to treat exocrine pancreatic insufficiency in patients with cystic fibrosis in early August. We expect to report topline efficacy data in the fourth quarter of 2016.